RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET ANALYSIS

Key Developments

• In May 2024, Aktis Oncology, biotechnology company has entered a multi-target discovery collaboration with Eli Lilly and Company to develop anticancer radiopharmaceuticals using Aktis' miniproteintechnology platform. The partnership combines Aktis' innovative radiopharmaceutical platform with Lilly's oncology expertise to create first-in-class treatments for various solid tumors.
• In March 2024, Ratio Therapeutics Inc. has announced an expanded manufacturing agreement with PharmaLogic to accelerate the development and commercialization of its next-generation radiotherapies. This collaboration will enhance the production of Ratio's fibroblast activation protein-alpha (FAP)-targeted radiotherapeutic candidate.
• In October 2022, Eclipse, a venture capital firm focused on digital transformation in physical industries, and Mayo Clinic have announced the creation of Nucleus RadioPharma. This new company, seeded with funding, aims to enhance the accessibility of lifesaving radiopharmaceuticals for cancer patients by modernizing their clinical development, manufacturing, and supply chain processes.
• In December 2023, Bristol Myers Squibb has announced it will acquire RayzeBio, Inc. for $62.50 per share in cash, totaling approximately US$4.1 billion or US$3.6 billion net of estimated cash acquired. The deal, approved by both companies' Boards, will enhance Bristol Myers Squibb's portfolio with RayzeBio's innovative actinium-based radiopharmaceutical therapeutics (RPTs). RayzeBio, a clinical-stage company, focuses on RPTs targeting solid tumors like GEP-NETs, small cell lung cancer, and hepatocellular carcinoma, offering potential advantages in efficacy and targeted delivery.